Edition:
United States

Becton Dickinson and Co (BDX.N)

BDX.N on New York Stock Exchange

205.30USD
21 Jul 2017
Change (% chg)

$1.97 (+0.97%)
Prev Close
$203.33
Open
$202.83
Day's High
$205.73
Day's Low
$202.83
Volume
486,560
Avg. Vol
371,265
52-wk High
$205.73
52-wk Low
$161.31

BDX.N

Chart for BDX.N

About

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of... (more)

Overall

Beta: 1.07
Market Cap(Mil.): $46,413.71
Shares Outstanding(Mil.): 226.08
Dividend: 0.73
Yield (%): 1.42

Financials

  BDX.N Industry Sector
P/E (TTM): 34.01 32.10 15.85
EPS (TTM): 6.04 -- --
ROI: 6.26 13.54 -8.31
ROE: 16.81 15.90 -7.95

BRIEF-BD receives FDA clearance for new immunological diagnostic system

* BD receives FDA 510(k) clearance for new immunological diagnostic system Source text for Eikon: Further company coverage:

Jul 19 2017

BRIEF-BD reports extension of exchange offers and consent solicitations for C. R. Bard notes

* BD announces extension of exchange offers and consent solicitations for C. R. Bard Inc notes

Jul 03 2017

Europe M&A surges but U.S. slows sharply amid uncertainty

Acquisitions of European companies surged in recent months, amid optimism about the region's economic prospects, but global deal-making subsided and the total value of U.S. deals fell sharply due to uncertainty about President Donald Trump's tax reform and deregulation agenda.

Jun 29 2017

Europe M&A surges but U.S. slows sharply amid uncertainty

June 29 Acquisitions of European companies surged in recent months, amid optimism about the region's economic prospects, but global deal-making subsided and the total value of U.S. deals fell sharply due to uncertainty about President Donald Trump's tax reform and deregulation agenda.

Jun 29 2017

BRIEF-FlowJo says established a strategic relationship with Becton Dickinson to catalyze coordination of resources for research market

* Flowjo- Co, Becton Dickinson have established a strategic relationship to catalyze coordination of resources, people and data for research market

Jun 13 2017

BRIEF-Becton Dickinson & Co and Bard get second requests from ftc under Hart-Scott-Rodino Act

* Becton Dickinson and Co says co, Bard get second requests from ftc under Hart-Scott-Rodino act; cos continue to expect transaction to close in the fall of 2017‍​‍​ Source text for Eikon: Further company coverage:

Jun 09 2017

BRIEF-BD receives FDA 510(k) clearance for molecular test for harmful intestinal bacteria causing infectious diarrhea

* BD receives FDA 510(K) clearance for molecular test for harmful intestinal bacteria causing infectious diarrhea Source text for Eikon: Further company coverage:

Jun 05 2017

BRIEF-BD announces extension of exchange offers, consent solicitations for C. R. Bard notes

* BD announces extension of exchange offers and consent solicitations for C. R. Bard, Inc notes

Jun 05 2017

Fitch Rates Becton, Dickinson and Company's Senior Euro Notes 'BBB-'; Outlook Stable

(The following statement was released by the rating agency) NEW YORK, May 23 (Fitch) Fitch Ratings has assigned a 'BBB-' rating to Becton, Dickinson and Company's (BDX) senior unsecured Euro notes offering. The company intends to use the net proceeds from the offering to fund the purchase of existing notes pursuant to the tender, to fund the purchase and retirement of debt in open market transactions, or otherwise, for general corporate purposes. A full list of ratings appears at the end of the

May 23 2017

BRIEF-Becton Dickinson and files pricing term sheet related to its 7-part notes offering

* Files pricing term sheet related to its 7-part notes offering Source text: (http://bit.ly/2q6pamG) Further company coverage:

May 23 2017

Earnings vs. Estimates